HD-OPM Archive
Topics › Plaque, CAC & CT angiography

EVAPORATE: high-dose EPA reversed plaque in patients with triglycerides above 135 mg/dL

Louis Nervegna · May 04, 2026 · ♥ 24 reactions · 37 comments · original Facebook post
Plaque, CAC & CT angiographySupplements & vitaminsFats & oils (saturated fat, seed oils, omega-6, olive oil)
AI summary & key facts

Louis summarizes the EVAPORATE randomized trial, where purified EPA (icosapent ethyl) shrank coronary plaque in patients with elevated triglycerides, and warns high doses can increase AFib.

High dose EPA from fish oil can reverse plaque.

These results are from the EVAPORATE randomized trial.

The participants all had triglycerides above 135 mg/dL, before starting the EPA fish oil.

Link to full study:

Paper · European Heart JournalEuropean Heart Journal articleacademic.oup.com

One of our group members Bob Harris reported a large reversal of plaque in his LAD (widowmaker) artery using high dose EPA. See this post: facebook.com/share/p/1D22zt8TKj.

Warning:

Doses of fish oil this high can increase the risk of developing AFIB. This needs to be seriously considered. Talk to your doctor before starting high doses of fish oil.

Quoted:

“A drug made from a highly purified form of EPA (an omega-3 fatty acid found in fish) appears to help reduce plaque in the heart's arteries, according to a study published online Aug. 29, 2020, by the European Heart Journal. The findings may explain why the drug, icosapent ethyl (Vascepa), lowers the risk of heart attack and stroke by 26% in people at high risk for those serious problems.

The study included 80 people with fatty plaque in the arteries of the heart (coronary artery disease). Most of them had diabetes and were taking a statin. Their trigly­cerides were elevated, ranging from 135 to 499 milligrams per deciliter. Half were randomly assigned to take 4 grams of icosapent ethyl daily; the other half received a placebo.

After 18 months, imaging tests showed that compared with the placebo group, the group taking the drug had less unstable (dangerous) plaque. The total volume of plaque was also lower among those taking the drug.”

Note:

Evidence from the large REDUCE-IT randomized trial demonstrates that Vascepa (icosapent ethyl) reduces the risk of heart attacks and other cardiovascular events, such as stroke or cardiovascular death, in patients whose triglyceride levels are above 135 mg/dL:

Paper · Circulation · 2020REDUCE-IT USABackground: Some trials have found that patients from the United States derive less benefit than patients enrolled outside the United States. This prespecified REDUCE-IT (Reduction of Cardiovascular Events with Icosapent Ethyl - Intervention Trial) subgroup analysis was conducted to determine the degree of benefit of icosapent ethyl in the United States. Methods: REDUCE-IT randomized 8179 statin-treated patients…ahajournals.org

Vascepa is high dose EPA from fish oil. It is FDA approved to lower cardiovascular risk, not just to lower triglycerides.

#reverseHD #epaHD #fishoilHD #omega3HD #budoffHD #vascepaHD #evaporateHD

Harvard HealthFish oil drug helps shrink plaque in heart arteries - Harvard HealthA drug made from a highly purified form of EPA (an omega-3 fatty acid found in fish) appears to help reduce plaque in the heart's arteries. This may explain why the drug, icosapent ethyl (Vascepa),...harvardhealth.org

Research cited

← newer: At least six interventions reverse plaque in RCTs, from weigolder: Five RCT-backed ways to reverse plaque; DASH in DISCO-CT was →